Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.

Samuel P, Pink RC, Caley DP, Currie JM, Brooks SA, Carter DR.

Tumour Biol. 2016 Feb;37(2):2565-73. doi: 10.1007/s13277-015-4081-z. Epub 2015 Sep 19.

PMID:
26386726
2.

The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.

Pink RC, Samuel P, Massa D, Caley DP, Brooks SA, Carter DR.

Gynecol Oncol. 2015 Apr;137(1):143-51. doi: 10.1016/j.ygyno.2014.12.042. Epub 2015 Jan 8.

PMID:
25579119
3.

miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.

van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, Pothof J, Wiemer EA.

Oncogene. 2013 Sep 5;32(36):4284-93. doi: 10.1038/onc.2012.433. Epub 2012 Oct 8.

PMID:
23045278
4.

DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through MAFG Overexpression in Cancer Cells.

Vera O, Jimenez J, Pernia O, Rodriguez-Antolin C, Rodriguez C, Sanchez Cabo F, Soto J, Rosas R, Lopez-Magallon S, Esteban Rodriguez I, Dopazo A, Rojo F, Belda C, Alvarez R, Valentin J, Benitez J, Perona R, De Castro J, Ibanez de Caceres I.

Theranostics. 2017 Sep 22;7(17):4118-4134. doi: 10.7150/thno.20112. eCollection 2017.

5.

A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.

Liu W, Wang S, Zhou S, Yang F, Jiang W, Zhang Q, Wang L.

Mol Biosyst. 2017 Oct 24;13(11):2268-2276. doi: 10.1039/c7mb00362e.

PMID:
28861582
6.

MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.

Li N, Yang L, Wang H, Yi T, Jia X, Chen C, Xu P.

PLoS One. 2015 Jun 4;10(6):e0128886. doi: 10.1371/journal.pone.0128886. eCollection 2015.

7.

MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.

Chen S, Jiao JW, Sun KX, Zong ZH, Zhao Y.

Drug Des Devel Ther. 2015 Sep 16;9:5225-35. doi: 10.2147/DDDT.S87526. eCollection 2015.

8.

Role of microRNAs in drug-resistant ovarian cancer cells.

Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C.

Gynecol Oncol. 2008 Dec;111(3):478-86. doi: 10.1016/j.ygyno.2008.08.017. Epub 2008 Sep 26.

PMID:
18823650
9.

Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.

Zhang X, Huang L, Zhao Y, Tan W.

Acta Biochim Biophys Sin (Shanghai). 2013 Dec;45(12):995-1001. doi: 10.1093/abbs/gmt113. Epub 2013 Oct 20.

PMID:
24145606
10.

MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.

Xiao F, Li Y, Wan Y, Xue M.

Cancer Chemother Pharmacol. 2018 May;81(5):935-947. doi: 10.1007/s00280-018-3548-1. Epub 2018 Mar 28.

PMID:
29594361
11.

MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.

Rao YM, Shi HR, Ji M, Chen CH.

J Huazhong Univ Sci Technolog Med Sci. 2013 Aug;33(4):567-572. doi: 10.1007/s11596-013-1160-5. Epub 2013 Aug 1.

PMID:
23904379
12.

miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.

Sun J, Cai X, Yung MM, Zhou W, Li J, Zhang Y, Li Z, Liu SS, Cheung ANY, Ngan HYS, Li Y, Dai Z, Kai Y, Tzatsos A, Peng W, Chan DW, Zhu W.

Oncogene. 2019 Jan;38(4):564-580. doi: 10.1038/s41388-018-0459-x. Epub 2018 Aug 30.

PMID:
30166592
13.

miR-509-3p enhances platinum drug sensitivity in ovarian cancer.

Niu L, Ni H, Hou Y, Du Q, Li H.

Gene. 2019 Feb 20;686:63-67. doi: 10.1016/j.gene.2018.11.011. Epub 2018 Nov 5.

PMID:
30408550
14.

Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility.

Ziliak D, Gamazon ER, Lacroix B, Kyung Im H, Wen Y, Huang RS.

Mol Cancer Ther. 2012 Sep;11(9):2054-61. doi: 10.1158/1535-7163.MCT-12-0221. Epub 2012 Jun 29.

15.

The regulation of miRNA-211 expression and its role in melanoma cell invasiveness.

Mazar J, DeYoung K, Khaitan D, Meister E, Almodovar A, Goydos J, Ray A, Perera RJ.

PLoS One. 2010 Nov 1;5(11):e13779. doi: 10.1371/journal.pone.0013779.

16.

MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1.

Liu Y, Niu Z, Lin X, Tian Y.

Cancer Gene Ther. 2017 May;24(5):208-214. doi: 10.1038/cgt.2017.6. Epub 2017 Mar 10.

PMID:
28281524
17.

MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.

Zhao H, Yu X, Ding Y, Zhao J, Wang G, Wu X, Jiang J, Peng C, Guo GZ, Cui S.

Oncotarget. 2016 Aug 16;7(33):53254-53268. doi: 10.18632/oncotarget.10736.

18.

Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.

Wu D, Lu P, Mi X, Miao J.

Arch Gynecol Obstet. 2018 Mar;297(3):699-707. doi: 10.1007/s00404-018-4649-0. Epub 2018 Jan 11.

PMID:
29327155
19.

Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance.

Li B, Chen H, Wu N, Zhang WJ, Shang LX.

Int J Gynecol Cancer. 2014 Oct;24(8):1381-8. doi: 10.1097/IGC.0000000000000252.

PMID:
25248111
20.

MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.

Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y, Li F, Han D, Wang L, Zhang G, Gao X.

Oncogene. 2014 Jan 16;33(3):378-86. doi: 10.1038/onc.2012.575. Epub 2013 Jan 14.

PMID:
23318422

Supplemental Content

Support Center